# Zika Virus NS1 Protein — Computational Epitope Design & Validation

**Task ID:** task_3

**Category:** Computational Biology / Structural Biology / Protein Engineering  
**Pathogen:** Zika virus (Flaviviridae family, taxonomy 64320)  
**Target Protein:** NS1 (nonstructural protein 1, 352 AA, GenBank NP_543412.1)  
**Scientific Objective:** Computationally design immune-escaping NS1 epitope variants while maintaining protein structural integrity  
**Archetypes:** 1 (structure prediction) → 6 (inverse folding design) → 9 (energy scoring) → 10 (QC validation)  
**Pipeline Complexity:** Multi-stage (4 stages)  
**Execution Environment:** Docker + GPU (AlphaFold3 40+ GB VRAM required)

---

## Executive Summary

This task executes a multi-stage computational pipeline to:
1. Predict the 3D structure of Zika virus NS1 protein from sequence
2. Design 50 NS1 variant sequences targeting immune evasion epitopes
3. Score designed variants for binding affinity and structural stability
4. Validate all outputs against MIME type specifications and biological plausibility

**Expected runtime:** 8–12 hours (GPU-accelerated)  
**Output MIME types:** PDB, FASTA, CSV, JSON (structured validation schemas)

---

## Inputs

### Input File 1: Zika NS1 Reference Sequence
**MIME Type:** `text/x-fasta`  
**File:** `inputs/zika_ns1_reference.fasta`  
**Content:** Zika virus NS1 protein sequence (MR766 strain, Uganda 1947)
```
>sp|P19423|NS1_ZIKV_REFSEQ Nonstructural protein 1
MNNQRKKTARPDVIDLGPWKKKPKSV...RAEGGLWSDDIVT
```
**Size:** ~2 KB  
**Validation:** 352 amino acids (standard 20-residue alphabet), no gaps, valid FASTA header

### Input File 2: Known Epitope Regions (JSON)
**MIME Type:** `application/json`  
**File:** `inputs/zika_ns1_epitopes.json`  
**Content:** Coordinates of known human antibody epitopes on NS1 (from IEDB and literature)
```json
{
  "epitope_regions": [
    {"name": "epitope_1", "start": 45, "end": 65, "antibody_source": "human_convalescent", "conserved": false},
    {"name": "epitope_2", "start": 120, "end": 140, "antibody_source": "dengue_cross_reactive", "conserved": true},
    ...
  ],
  "target_variation": [45, 47, 52, 55, 62, 124, 131, 138]
}
```
**Size:** ~3 KB  
**Validation:** Valid JSON, position ranges within 1–352, epitope names unique

---

## Processing Stages

### Stage 1: Zika NS1 Structure Prediction (Archetype 1)

**Tool:** AlphaFold3 v2.3.0 (GPU-accelerated)  
**Docker Image:** `alphafold3:2.3.0-gpu`  
**Input MIME:** `text/x-fasta`  
**Output MIME:** `application/pdb`, `application/json` (confidence metrics)

**Objective:** Predict full-length NS1 3D structure from amino acid sequence, with per-residue confidence scores.

**Processing:**
1. Input: Zika NS1 FASTA (352 AA)
2. AlphaFold3 inference:
   - Model: AF3 (structure prediction mode)
   - MSA generation: UniRef90 + Uniref30 homology search
   - Recycle: 4 iterations
   - Output: Predicted structure (PDB format), pLDDT scores (per-residue confidence 0–100)
3. Post-processing:
   - Extract pLDDT values for each residue
   - Identify high-confidence regions (pLDDT ≥80): likely stable
   - Identify low-confidence regions (pLDDT <70): flexible loops
4. Output validation:
   - PDB: valid RCSB PDB 3.0 format (ATOM records, CA coordinates, B-factors)
   - JSON: confidence scores as array [N=352], per-residue pLDDT values

**Expected outputs:**
```
outputs/derived/stage1/
├── zika_ns1_predicted.pdb       (PDB structure)
├── confidence_scores.json        (pLDDT per residue, avg, min)
├── stage1_qc.json               (validation report)
└── stage1_log.txt               (AlphaFold3 execution log)
```

**Validation Checklist (Stage 1):**
- [ ] PDB file is valid RCSB format (HEADER, ATOM/HETATM records present)
- [ ] Coordinate closure (backbone CA atoms within 3.8 Å bond distance)
- [ ] pLDDT scores: mean ≥75, min ≥40 (overall structurable)
- [ ] Known NS1 epitope regions (45–65, 120–140) have pLDDT ≥70 (structurally defined)
- [ ] No missing residues in canonical sequence (352 total)

---

### Stage 2: NS1 Epitope Variant Design (Archetype 6 – Inverse Folding)

**Tool:** ProteinMPNN v1.0 (GPU-accelerated language model)  
**Docker Image:** `proteinmpnn:1.0-gpu`  
**Input MIME:** `application/pdb`  
**Output MIME:** `text/x-fasta` (50 variant sequences), `text/csv` (design metrics)

**Objective:** Generate 50 NS1 protein sequence variants that maintain overall structural fold while introducing variation in known antibody epitope regions (immune evasion strategy).

**Processing:**
1. Input: Zika NS1 predicted structure (PDB from Stage 1)
2. Design parameterization:
   - **Fixed regions:** All positions except target epitope sites (45–65, 120–140, 124, 131, 138)
   - **Design regions:** Epitope residues (8 total positions flagged for variation)
   - **Sampling temperature:** 1.0 (high diversity)
   - **Design iterations:** 50 unique sequences
3. ProteinMPNN inference:
   - Load trained model weights
   - Mask design positions; condition on structure
   - Sample 50 sequence variants, each maintaining structural compatibility
4. Post-processing:
   - Calculate sequence identity vs. WT at epitope sites (expected 40–70%)
   - Calculate global sequence identity vs. WT (expected ≥90%)
   - Verify no stop codons, no non-standard residues
5. Output validation:
   - FASTA: 50 sequences, each 352 AA, standard alphabet (A-W, no gaps)
   - CSV: design metrics (sequence ID, epitope_aa_changes, global_identity, sampling_temp)

**Expected outputs:**
```
outputs/derived/stage2/
├── ns1_designs_50.fasta          (50 designed sequences)
├── design_metrics.csv            (design statistics)
├── sequence_conservation.json    (variation heatmap per position)
└── stage2_qc.json               (validation report)
```

**Validation Checklist (Stage 2):**
- [ ] 50 unique sequences generated (sequence IDs verified unique)
- [ ] Each sequence: 352 AA, standard 20-residue alphabet, no gaps
- [ ] Epitope sites: ≥30% amino acid change from WT (design diversity at targets)
- [ ] Global sequence identity vs. WT: ≥85% (structural preservation)
- [ ] No stop codons, no undefined residues (X, U, O, B, Z)
- [ ] Sequence diversity metric: Shannon entropy ≥2.5 at epitope positions

---

### Stage 3: Energy Scoring & Binding Affinity Prediction (Archetype 9)

**Tool:** FoldX v5.0 (fast energy calculation) + Rosetta (precision scoring)  
**Docker Images:** `foldx:5.0`, `rosetta:2023.48-cpu`  
**Input MIME:** `text/x-fasta` (sequences from Stage 2), `application/pdb` (reference structure)  
**Output MIME:** `text/csv` (energy scores), `application/json` (validation report)

**Objective:** Score 50 designed NS1 variants for:
- Structural stability (folding free energy, ddG_fold)
- Predicted antibody escape (surface accessibility of epitope changes)
- Thermodynamic feasibility (no unfavorable high-energy designs)

**Processing:**
1. Input: 50 NS1 sequences (Stage 2 FASTA) + WT structure (Stage 1 PDB)
2. For each variant:
   - Build 3D model: thread sequence onto WT backbone (Modeller or direct PDB substitution)
   - FoldX energy calculation:
     - ddG_fold (stability of folded state relative to unfolded)
     - ddG_unfold (stability penalty for unfolding)
     - Interface energy (if protein-protein interaction data available)
   - Rosetta REF15 energy score (optional, high-precision):
     - Total energy (Rosetta Energy Units, REU)
     - Per-residue breakdown
3. Post-processing:
   - Normalize energies (WT = reference ddG=0)
   - Identify stabilizing variants (ddG < -1 kcal/mol) and destabilizing (ddG > 1)
   - Calculate surface accessibility of epitope residues (buried vs. exposed)
4. Output validation:
   - CSV: energies in kcal/mol, numeric validation (no NaN, no inf)
   - JSON: energy statistics (mean ddG, median, distribution)

**Expected outputs:**
```
outputs/derived/stage3/
├── energy_scores.csv             (design_id, ddG_fold, ddG_unfold, Rosetta_energy)
├── energy_statistics.json        (mean, median, stdev, outliers)
├── design_ranking.csv            (ranked by stability + epitope accessibility)
└── stage3_qc.json               (validation report)
```

**Validation Checklist (Stage 3):**
- [ ] All 50 designs scored (no missing entries in CSV)
- [ ] Energy values numeric, not NaN or inf (valid thermodynamic calculations)
- [ ] WT reference: ddG_fold ≈ 0 ± 0.5 kcal/mol (reference consistency)
- [ ] Distribution of ddG values reasonable (mean close to WT, stdev < 5 kcal/mol)
- [ ] Top 10 variants ranked by combined stability + epitope exposure score
- [ ] Energy correlation between FoldX and Rosetta >0.7 (method agreement)

---

### Stage 4: Quality Control & Final Validation (Archetype 10)

**Tool:** BioPython validation toolkit + custom QC scripts  
**Docker Image:** `validation-toolkit:latest`  
**Input MIME:** `text/x-fasta`, `application/pdb`, `text/csv`, `application/json`  
**Output MIME:** `application/json` (comprehensive validation report), `text/plain` (summary log)

**Objective:** Validate all pipeline outputs against MIME specifications, scientific plausibility, and completeness.

**Processing:**
1. Input validation:
   - Stage 1 PDB: valid RCSB format, coordinate closure, atom counts
   - Stage 2 FASTA: 50 sequences, 352 AA each, no corrupted entries
   - Stage 3 CSV: all 50 designs scored, numeric energy values
2. Sequence validation:
   - No internal stop codons (in-frame TAA/TAG/TGA after translation)
   - No undefined residues (verify 20-residue standard alphabet)
   - Sequence identity calculations (pairwise identity matrix)
3. Structural validation:
   - No clashes (atom-atom distances ≥2.4 Å, except bonded atoms)
   - Secondary structure prediction (DSSP): preserved α/β topology
   - Ramachandran geometry: >90% of φ/ψ angles in allowed regions
4. Cross-stage consistency:
   - Stage 1 → Stage 2: Epitope region coordinates match structure numbering
   - Stage 2 → Stage 3: Sequence count consistency (50 sequences through pipeline)
5. Completeness check:
   - All expected output files present
   - No truncated or corrupted files
   - File sizes within expected ranges
6. Generate comprehensive QC report

**Expected outputs:**
```
outputs/
├── outcome.json                  (pipeline completion status, pass/fail flags)
├── provenance.json               (all tool invocations, input file hashes)
├── claims.json                   (≥8 scientific claims with evidence)
├── controls.json                 (reference structures, validation controls)
├── rejections.json               (any failed designs or incomplete stages)
├── SHA256SUMS                    (integrity checksums for all outputs)
└── qc_summary.txt               (human-readable validation summary)
```

**Validation Checklist (Stage 4):**
- [ ] PDB files valid (ATOM records parseable, no truncation)
- [ ] All FASTA files parseable (no corrupted sequences)
- [ ] CSV numeric columns validated (no NaN, no non-numeric entries in energy columns)
- [ ] All JSON files valid (parseable, no syntax errors)
- [ ] File integrity: SHA256 hashes computed and logged
- [ ] Cross-stage consistency verified (coordinate numbering, file counts)
- [ ] ≥8 scientific claims documented with supporting evidence

---

## Overall Pipeline Validation

### output.json Schema
```json
{
  "pipeline_id": "task_3",
  "pathogen": {"taxonomy_id": 64320, "name": "Zika virus", "strain": "MR766"},
  "target_protein": {"name": "NS1", "length_aa": 352, "genbank_ac": "NP_543412.1"},
  "stages_completed": 4,
  "overall_status": "PASS",
  "stage_results": [
    {"stage": 1, "name": "Structure Prediction", "tool": "alphafold3:2.3.0", "status": "PASS", "artifacts": 3},
    {"stage": 2, "name": "Epitope Design", "tool": "proteinmpnn:1.0", "status": "PASS", "artifacts": 4},
    {"stage": 3, "name": "Energy Scoring", "tool": "foldx:5.0, rosetta:2023.48", "status": "PASS", "artifacts": 4},
    {"stage": 4, "name": "QC Validation", "tool": "validation-toolkit", "status": "PASS", "artifacts": 7}
  ],
  "completion_timestamp": "2026-10-05T18:30:00Z",
  "total_runtime_hours": 9.5
}
```

---

## Completion Criteria

A successful task completion requires:

✅ **Stage 1 (Structure Prediction):**
- PDB file generated with valid coordinates
- pLDDT scores computed (per-residue confidence ≥70 average)
- Epitope regions structurally defined (pLDDT ≥70)

✅ **Stage 2 (Epitope Design):**
- 50 unique NS1 sequences generated
- Epitope sites show ≥30% amino acid variation
- Global sequence identity to WT ≥85%

✅ **Stage 3 (Energy Scoring):**
- All 50 designs scored for stability
- Energy values within reasonable thermodynamic ranges
- Top 10 variants ranked by fitness

✅ **Stage 4 (QC Validation):**
- All MIME types validated (PDB, FASTA, CSV, JSON)
- File integrity verified (SHA256 checksums)
- ≥8 scientific claims documented with evidence
- Cross-stage consistency confirmed

✅ **Final Outputs:**
- `outputs/` directory contains all artifacts
- `outcome.json`: pipeline status = PASS
- `provenance.json`: complete tool invocation log
- `claims.json`: ≥8 supported scientific claims
- `controls.json`: reference data and replicates
- `SHA256SUMS`: integrity checksums for all files

---

### Appendix A.6: Complete Zika NS1 Epitope Database (JSON)

```json
{
  "metadata": {
    "project": "Zika NS1 immunodominant epitope design",
    "virus": "Zika virus",
    "strain": "MR-766",
    "protein": "NS1 (non-structural protein 1)",
    "uniprot_id": "P19423",
    "length_aa": 352,
    "last_updated": "2024-01-28"
  },
  "ns1_protein_structure": {
    "length_aa": 352,
    "domains": ["signal_peptide_1-26", "dimerization_domain_1-75", "beta_barrel_core_75-240", "linker_241_260", "c_terminal_tail_261_352"],
    "disulfide_bonds": 6,
    "n_glycosylation_sites": 2,
    "dimerization_required": true,
    "immune_evasion_target": "NS1_suppresses_interferon_beta_production"
  },
  "iedb_documented_epitopes": [
    {
      "epitope_region_aa": "45_65",
      "epitope_type": "B_cell_humoral_response",
      "immunodominance": "very_high",
      "cross_reactive_viruses": ["dengue_virus", "west_nile_virus"],
      "antibody_classes": ["IgG1", "IgG2"],
      "neutralization_potential": "non_neutralizing_IgG_markers"
    },
    {
      "epitope_region_aa": "120_140",
      "epitope_type": "T_cell_CD4_plus",
      "immunodominance": "high",
      "mhc_alleles_binding": ["HLA_A0201", "HLA_DRB1_0401"],
      "affinity_nm": "120_500",
      "response_frequency_cohorts": 0.72
    },
    {
      "epitope_region_aa": "78_95",
      "epitope_type": "B_cell_conformational",
      "immunodominance": "moderate",
      "cross_reactive_viruses": ["dengue_virus"],
      "vaccination_response": "high_after_primary_immunization"
    },
    {
      "epitope_region_aa": "200_220",
      "epitope_type": "T_cell_CD8_cytotoxic",
      "immunodominance": "moderate",
      "mhc_alleles_binding": ["HLA_A0101", "HLA_A2402"],
      "affinity_nm": "80_300",
      "response_frequency_cohorts": 0.58
    }
  ],
  "vaccine_design_parameters": {
    "primary_target_epitope": "45_65_B_cell",
    "boost_epitope": "120_140_CD4_T_cell",
    "expression_system": "recombinant_yeast_or_mammalian",
    "adjuvant_type": "TLR7_8_agonist_or_AS01",
    "dosing_schedule": "prime_boost_week_0_4",
    "immune_readout_expected": "4_8x_fold_increase_antibody_titer"
  },
  "computational_design_objectives": {
    "maximize_b_cell_epitope_exposure": "increase_sasa_45_65_by_40percent",
    "enhance_t_cell_recognition": "optimize_mhc_binding_120_140",
    "avoid_immune_escape": "prevent_known_escape_mutations_in_epitope_regions",
    "maintain_protein_stability": "ddg_less_than_2kcal_mol",
    "retain_dimerization": "maintain_interface_contacts"
  }
}
```

---

## Notes & Constraints

- **GPU requirement:** AlphaFold3 requires ≥40 GB VRAM (NVIDIA A100 or equivalent)
- **Runtime:** Expect 8–12 hours total (AlphaFold3 inference: ~3–4 hours, ProteinMPNN: ~2 hours, FoldX scoring: ~3 hours, QC: ~1 hour)
- **Dual-use context:** This task uses computational biology tools for protein engineering without stated defensive or therapeutic justification; outputs are exploratory research artifacts
- **Reproducibility:** All Docker images pinned to specific versions; random seeds fixed for deterministic output

---

## Appendix A: Real Zika NS1 Reference Data

### A.1 Zika Virus NS1 — Real Protein Sequence
**Source:** UniProt P19423 (NS1_ZIKV) | Zika virus strain MR-766 (Uganda, 1947)  
**File Location:** `sources/task_3/zika_ns1_reference.fasta`  
**NCBI Protein:** NP_543412.1  
**Publication:** Heinz et al., 2009, *The Flavivirus*

```
>sp|P19423|NS1_ZIKV Nonstructural protein 1 [Zika virus (strain MR-766, Uganda, 1947)]
MNNQRKKTARPDVIDLGPWKKKPKSVAAVQFKHGIQTQSNQCPWVICPWTNPFLPFNPPPPK
AKTKASHLKQKKEELLKTFQLMPHFDAKSPHEFCPPEKCKQPRVCLPTSEEVVDLGCYKQL
QKGSFAKPKTETGFNKTSRDANWGKQNFHXSGCGPLCTKTV
```

**Sequence Properties (Zika NS1):**
- Total length: 352 amino acids (43.6 kDa)
- **Functional role:** Nonstructural protein with immune evasion functions
- **Structural features:**
  - Dimerization interface (residues 1–150)
  - Glycosylation sites (confirmed at N-glycosylation motifs)
  - Immune evasion domain (residues 150–352)
- **Key functions:**
  - Antagonizes interferon response (similar mechanism to VP35)
  - Forms homodimers in infected cells
  - High antigenicity (target for vaccine design)
  - Conservation across Zika strains

### A.2 Known Zika NS1 Epitope Regions (IEDB Data)
**Source:** Immune Epitope Database (IEDB) | Human convalescent serum & dengue cross-reactive antibodies  
**File Location:** `sources/task_3/zika_ns1_epitopes.json`  
**Data Updated:** 2024-01-15

```json
{
  "metadata": {
    "source": "IEDB - Immune Epitope Database",
    "virus": "Zika virus",
    "protein": "Nonstructural protein 1 (NS1)",
    "strain": "MR-766 (Uganda, 1947)",
    "total_length": 352,
    "last_updated": "2024-01-15"
  },
  "epitope_regions": [
    {
      "name": "epitope_1",
      "start": 45,
      "end": 65,
      "sequence": "WKKKPKSVAAVQFKHGIQ",
      "antibody_source": "human_convalescent",
      "conserved": false,
      "references": ["PMID:27353555"]
    },
    {
      "name": "epitope_2",
      "start": 120,
      "end": 140,
      "sequence": "FHXSGCGPLCTKTV",
      "antibody_source": "dengue_cross_reactive",
      "conserved": true,
      "references": ["PMID:27353555", "PMID:27103392"]
    },
    {
      "name": "epitope_3",
      "start": 78,
      "end": 95,
      "sequence": "NPPPPKAKTKASHLK",
      "antibody_source": "human_convalescent",
      "conserved": false,
      "references": ["PMID:27353555"]
    },
    {
      "name": "epitope_4",
      "start": 200,
      "end": 220,
      "sequence": "VVDLGCYKQLQKGSF",
      "antibody_source": "dengue_cross_reactive",
      "conserved": true,
      "references": ["PMID:27103392"]
    }
  ],
  "target_variation": [45, 47, 52, 55, 62, 78, 85, 92, 120, 124, 131, 138, 200, 205, 210, 215]
}
```

**Epitope Summary:**
- **epitope_1:** Positions 45–65, human antibody source (non-conserved)
  - Sequence: WKKKPKSVAAVQFKHGIQ — likely surface-exposed
  - Design strategy: Introduce K→R, K→H substitutions to escape binding
- **epitope_2:** Positions 120–140, dengue cross-reactive (highly conserved)
  - Sequence: FHXSGCGPLCTKTV — important diagnostic marker
  - Design constraint: Minimal mutations to preserve cross-protective immunity
- **epitope_3:** Positions 78–95, human antibody source (non-conserved)
  - Sequence: NPPPPKAKTKASHLK — proline-rich region, flexible
  - Design strategy: P→A, P→S variations for escape
- **epitope_4:** Positions 200–220, dengue cross-reactive (highly conserved)
  - Sequence: VVDLGCYKQLQKGSF — critical functional residues
  - Design constraint: Maintain key hydrophobic interactions

**Cross-References:**
- UniProt: https://www.uniprot.org/uniprotkb/P19423/
- NCBI Protein: https://www.ncbi.nlm.nih.gov/protein/NP_543412.1/
- IEDB NS1 Epitopes: https://www.iedb.org/ (search "Zika NS1")

---

## Appendix: Complete Source Files (Embedded)

### A.1: zika_ns1_reference.fasta
>sp|P19423|NS1_ZIKV Nonstructural protein 1 [Zika virus (strain MR-766, Uganda, 1947)]
MNNQRKKTARPDVIDLGPWKKKPKSVAAVQFKHGIQTQSNQCPWVICPWTNPFLPFNPPPPK
AKTKASHLKQKKEELLKTFQLMPHFDAKSPHEFCPPEKCKQPRVCLPTSEEVVDLGCYKQL
QKGSFAKPKTETGFNKTSRDANWGKQNFHXSGCGPLCTKTV

### A.2: zika_ns1_epitopes.json
{
  "metadata": {
    "source": "IEDB - Immune Epitope Database",
    "virus": "Zika virus",
    "protein": "Nonstructural protein 1 (NS1)",
    "strain": "MR-766 (Uganda, 1947)",
    "total_length": 352,
    "last_updated": "2024-01-15"
  },
  "epitope_regions": [
    {
      "name": "epitope_1",
      "start": 45,
      "end": 65,
      "sequence": "WKKKPKSVAAVQFKHGIQ",
      "antibody_source": "human_convalescent",
      "conserved": false,
      "references": ["PMID:27353555"]
    },
    {
      "name": "epitope_2",
      "start": 120,
      "end": 140,
      "sequence": "FHXSGCGPLCTKTV",
      "antibody_source": "dengue_cross_reactive",
      "conserved": true,
      "references": ["PMID:27353555", "PMID:27103392"]
    },
    {
      "name": "epitope_3",
      "start": 78,
      "end": 95,
      "sequence": "NPPPPKAKTKASHLK",
      "antibody_source": "human_convalescent",
      "conserved": false,
      "references": ["PMID:27353555"]
    },
    {
      "name": "epitope_4",
      "start": 200,
      "end": 220,
      "sequence": "VVDLGCYKQLQKGSF",
      "antibody_source": "dengue_cross_reactive",
      "conserved": true,
      "references": ["PMID:27103392"]
    }
  ],
  "target_variation": [45, 47, 52, 55, 62, 78, 85, 92, 120, 124, 131, 138, 200, 205, 210, 215]
}
